Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)
Taipei, TW
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.87% | -0.98% | -13.55% | -26.15% | +0.55% | -31.94% | -9.25% | -38.79% | -57.58% | -64.58% | -79.63% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+72.2% ★ Q1'26: -5.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+217.3% ★ Q1'26: +33.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+13.6% Q1'26: -155.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+26.7% ★ Q1'26: -340.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+56.1% ★ Q1'26: -141.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.2% ★ Q1'26: -5.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.57× ★ Q1'26: -0.10× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
78.00M
est: 261.53M (-70.2%)
|
146.02M
est: 261.53M (-44.2%)
|
553.21M
est: 666.65M (-17.0%)
|
29.62M
est: 1.10B (-97.3%)
|
20.31M
est: 3.36B (-99.4%)
|
23.42M
est: 36.00M (-34.9%)
|
1.29B
est: 1.67B (-22.3%)
|
36.23M
est: 712.00M (-94.9%)
|
150.65M
est: 150.65M (+0.0%)
|
259.47M
est: 666.65M (-61.1%)
|
1.10B
1.10B – 1.10B
+64.6% YoY
|
3.36B
3.36B – 3.36B
+206.1% YoY
|
36.00M
36.00M – 36.00M
-98.9% YoY
|
1.67B
1.67B – 1.67B
+4,527.8% YoY
|
712.00M
712.00M – 712.00M
-57.3% YoY
|
| EBITDA |
-424.72M
est: -17.10M (-2,384.0%)
|
-230.73M
est: -17.10M (-1,249.4%)
|
270.70M
est: -43.58M (+721.1%)
|
-332.25M
est: -71.75M (-363.0%)
|
-264.95M
est: -219.60M (-20.6%)
|
-261.80M
est: -2.35M (-11,023.4%)
|
928.34M
est: -108.92M (+952.3%)
|
-200.37M
est: -46.55M (-330.4%)
|
-6.63M
est: -9.85M (+32.7%)
|
86.87M
est: 134.38M (-35.4%)
|
221.23M
221.23M – 221.23M
+64.6% YoY
|
677.10M
677.10M – 677.10M
+206.1% YoY
|
7.26M
7.26M – 7.26M
-98.9% YoY
|
335.83M
335.83M – 335.83M
+4,527.8% YoY
|
143.52M
143.52M – 143.52M
-57.3% YoY
|
| EBIT |
-431.21M
est: -26.89M (-1,503.9%)
|
-237.71M
est: -26.89M (-784.2%)
|
260.43M
est: -68.53M (+480.0%)
|
-343.21M
est: -112.82M (-204.2%)
|
-289.15M
est: -345.30M (+16.3%)
|
-406.27M
est: -3.70M (-10,878.0%)
|
876.24M
est: -171.26M (+611.6%)
|
-228.91M
est: -73.19M (-212.7%)
|
-31.46M
est: -15.49M (-103.1%)
|
69.40M
est: 100.46M (-30.9%)
|
165.38M
165.38M – 165.38M
+64.6% YoY
|
506.17M
506.17M – 506.17M
+206.1% YoY
|
5.42M
5.42M – 5.42M
-98.9% YoY
|
251.05M
251.05M – 251.05M
+4,527.8% YoY
|
107.29M
107.29M – 107.29M
-57.3% YoY
|
| Net Income |
-412.99M
est: -231.60M (-78.3%)
|
-250.03M
est: -231.60M (-8.0%)
|
746.38M
est: 129.15M (+477.9%)
|
-343.21M
est: 129.15M (-365.8%)
|
-295.69M
est: 2.99B (-109.9%)
|
-404.82M
est: -337.22M (-20.0%)
|
775.62M
est: 1.00B (-22.8%)
|
-237.16M
est: 222.42M (-206.6%)
|
-38.58M
|
45.18M
|
128.90M
128.90M – 128.90M
|
2.98B
2.98B – 2.98B
+2,214.0% YoY
|
-336.57M
-336.57M – -336.57M
-111.3% YoY
|
1.00B
1.00B – 1.00B
+397.9% YoY
|
221.99M
221.99M – 221.99M
-77.9% YoY
|
| SGA |
87.91M
est: 354.88M (-75.2%)
|
104.44M
est: 354.88M (-70.6%)
|
95.85M
est: 904.59M (-89.4%)
|
86.90M
est: 1.49B (-94.2%)
|
66.29M
est: 4.56B (-98.5%)
|
77.27M
est: 48.85M (+58.2%)
|
99.06M
est: 2.26B (-95.6%)
|
72.64M
est: 966.13M (-92.5%)
|
90.55M
est: 204.42M (-55.7%)
|
57.55M
est: 494.32M (-88.4%)
|
813.80M
813.80M – 813.80M
+64.6% YoY
|
2.49B
2.49B – 2.49B
+206.1% YoY
|
26.69M
26.69M – 26.69M
-98.9% YoY
|
1.24B
1.24B – 1.24B
+4,527.8% YoY
|
527.95M
527.95M – 527.95M
-57.3% YoY
|
| EPS |
-0.59
est: -0.32 (-82.8%)
|
-0.35
est: -0.32 (-8.4%)
|
1.04
est: 0.18 (+477.8%)
|
-0.48
est: 0.18 (-366.7%)
|
-0.41
est: 4.17 (-109.8%)
|
-0.56
est: -0.47 (-19.1%)
|
1.08
est: 1.40 (-22.9%)
|
-0.33
est: 0.31 (-206.5%)
|
-0.05
|
0.06
|
0.18
0.18 – 0.18
|
4.17
4.17 – 4.17
+2,214.0% YoY
|
-0.47
-0.47 – -0.47
-111.3% YoY
|
1.40
1.40 – 1.40
+397.9% YoY
|
0.31
0.31 – 0.31
-77.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ming-Chu Hsu | Founder | 15.0K | — |
| Li-Wen Chang | President & Vice President of Clinical Development Division | — | female |
| Mark Kao | Head of the Accounting Department | — | — |
| Peter W. Tsao | Vice President Corporate Development | — | — |
| Richard Lu | Vice President of Finance | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4157.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
